Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotechnology companies file extensive documentation with the SEC, and Cue Biopharma's filings reveal the details investors need to evaluate drug development progress. The company's quarterly 10-Q and annual 10-K reports disclose cash burn rates, pipeline timelines, and the clinical trial data that drives biotech valuations.
For a company like Cue Biopharma without product revenue, SEC filings provide critical transparency into financial runway and operational priorities. The 10-K annual report details research and development expenses by program, partnership economics, and risk factors specific to immunotherapy development. Quarterly 10-Q filings track how quickly cash reserves are being deployed across clinical trials.
Form 8-K filings from Cue Biopharma often announce material events that move biotech stocks: clinical trial initiations, data readouts, FDA feedback, and strategic partnerships. These real-time disclosures can precede press releases and provide unfiltered information directly from regulatory filings.
Insider transaction data through Form 4 filings shows when executives and directors buy or sell CUE shares. For biotechnology companies approaching clinical catalysts, insider trading patterns can signal management confidence in upcoming milestones.
Our AI-powered tools simplify the technical language in Cue Biopharma's regulatory documents. Instead of parsing 100+ pages of accounting footnotes and legal disclosures, get clear explanations of what each filing means for the company's drug development programs and financial position.
Cue Biopharma is conducting a public offering of common stock, pre‑funded warrants and common stock warrants, all sold together as units. The pre‑funded warrants have a de minimis exercise price and are exercisable on a cashless basis, while the common stock warrants are exercisable for five years and may be cashless if no effective registration is available.
The company is a clinical‑stage biopharmaceutical developer using its Immuno‑STAT platform to target disease‑specific T cells in autoimmune diseases. As of September 30, 2025, it held $18.7 million in cash, cash equivalents and marketable securities and has a collaboration providing a $5.0 million upfront payment and a further $5.0 million time‑based payment due in December 2025, which together are expected to fund operations into the third quarter of 2026. Management states there is substantial doubt about the company’s ability to continue as a going concern and that proceeds from this offering will not be sufficient to remove that doubt, and notes that additional equity financing is likely to be dilutive.
Cue Biopharma, Inc. (CUE) reported a Form 4 transaction for its Chief Business Officer. The officer received a stock option grant covering 125,000 shares of Cue Biopharma common stock on 09/29/2025. The option has an exercise price of $0.72 per share and expires on 09/28/2035.
According to the filing, this stock option becomes fully exercisable on the first anniversary of the grant date, meaning the officer must wait one year before the option is fully vested. Following this grant, the officer beneficially owns 125,000 derivative securities, held directly. This transaction reflects equity-based compensation designed to align the officer’s interests with those of shareholders.
Cue Biopharma, Inc. (CUE) reported an equity award to its chief development officer. The reporting person received a stock option covering 50,000 shares of common stock at an exercise price of $0.72 per share on 09/29/2025. This option is scheduled to become fully exercisable on the first anniversary of the grant date and carries an expiration date of 09/28/2035. After this grant, the reporting person holds 50,000 derivative securities related to Cue Biopharma common stock with direct ownership.
Cue Biopharma, Inc. reported that on November 24, 2025 it made an updated corporate presentation publicly available on its website and furnished that presentation as Exhibit 99.1 to a Form 8-K. The company notes that the materials provided under Item 7.01, including the presentation, are being furnished rather than filed under the Exchange Act, which means they are not subject to certain liabilities associated with filed reports and are not automatically incorporated into other securities filings unless specifically referenced.
Cue Biopharma, Inc. (CUE) announced that Chief Medical Officer Matteo Levisetti will leave the company, with his employment ending on November 28, 2025. The company and Dr. Levisetti agreed to his separation on November 17, 2025.
Subject to signing and not revoking a separation and release of claims agreement, Dr. Levisetti will receive a lump-sum cash severance of $556,837.60, equal to nine months of base salary plus a prorated portion of his 2025 target bonus, paid in the first regular payroll cycle after the separation agreement becomes effective. If he elects COBRA coverage, Cue Biopharma will pay the full premiums for up to nine months after the Separation Date, or until he secures reasonably comparable new coverage or COBRA otherwise ends.
Cue Biopharma reported third‑quarter results, highlighting lower collaboration revenue and continued operating losses, alongside a new collaboration that adds near‑term cash. Collaboration revenue was
Liquidity remained tight with cash, cash equivalents and marketable securities of
Cue Biopharma (CUE) reported that it issued a press release with financial results for the quarter ended September 30, 2025. The release is furnished as Exhibit 99.1.
The company notes that the information in this report, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference, except as expressly set forth by specific reference.
Cue Biopharma (CUE) announced a Collaboration and License Agreement with ImmunoScape Pte. Ltd. (IMSCP), following IMSCP’s exercise of an option on
The structure grants IMSCP a co-exclusive development license for five years or longer (while a specified number of CUE‑100 Series molecules remain under active development), with Cue retaining non‑exclusive research rights to support other programs. IMSCP also receives an exclusive commercial license for any CUE‑100 Series molecule it advances to IND‑enabling studies during the co‑exclusive period.
Cue received
Cue Biopharma director and CEO Usman Azam was granted a stock option on 09/29/2025 to purchase 1,875,000 shares of common stock at an exercise price of $0.72 per share. The option was reported on Form 4 filed 10/02/2025 and becomes exercisable in 48 monthly installments beginning 09/29/2026, with an expiration date of 09/28/2035. After the grant, Azam beneficially owns 1,875,000 underlying shares directly. The filing was signed by an attorney-in-fact on Azam's behalf.
Usman Azam filed a Form 3 reporting his relationship to Cue Biopharma, Inc. (CUE) as both a director and the Chief Executive Officer. The form shows the date of event as 09/29/2025 and states that no securities are beneficially owned by the reporting person as of the filing. The filing was executed by an attorney-in-fact on 10/02/2025 and includes an exhibit: Exhibit 24.1 - Power of Attorney.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
